Negative Correlation between Serum Brain-derived Neurotrophic Factor Levels and Obesity Predictor Markers and Inflammation Levels in Females with Obesity

Slamet Raharjo1, Adi Pranoto2, Purwo Sri Rejeki2, A. S. M. Harisman1, Yualita Putri Pamungkas4, Olivia Andiana1

1Department of Sports Science, Faculty of Sports Science, State University of Malang, Malang, Indonesia; 2Department of Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; 3Department of Physiology and Medical Biochemistry, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; 4Department of Public Health, Faculty of Sports Science, State University of Malang, Malang, Indonesia

Abstract

BACKGROUND: Obesity has been widely associated with structural and functional changes in brain, whereas inflammation is one of the potential mechanisms involved in these changes.

AIM: This study aims to prove the relationship between serum brain-derived neurotrophic factor (BDNF) levels and obesity predictor markers (body mass index [BMI] and waist to hip ratio [WHR]) and inflammation (interleukin-6 [IL-6] and tumor necrosis factor-alpha [TNF-α]) levels in females with obesity.

METHODS: This study used a cross-sectional study method using 33 female with obesity aged 19–23 years, BMI ≥27.5 kg/m², normal blood pressure, normal resting heart rate, normal hemoglobin, and fasting blood glucose ≤100 mg/dL. The examination of serum BDNF, IL-6, and TNF-α levels using the Enzyme-Linked Immunosorbent Assay method. The data were analyzed using Pearson product-moment test with a significant level p < 0.05.

RESULTS: The results indicated that there is a negative correlation between serum BDNF levels and BMI (r = –0.759; p < 0.001), WHR (r = –0.675; p < 0.001), IL-6 levels (r = –0.530; p < 0.001), and TNF-α levels (r = –0.561; p < 0.001).

CONCLUSION: Based on the results of the study, there is a negative correlation between serum BDNF levels and BMI, WHR, and inflammation (IL-6 and TNF-α) levels in females with obesity. Further studies are needed to confirm the present findings.

Introduction

The worldwide prevalence of obesity nearly tripled between 1975 and 2016 [1]. Based on data from the WHO [1] reports, around 13% of the world’s population aged 18 years in 2016 were categorized as obese. Obesity is regarded as a condition of excessive fat accumulation, and thus it can affect individual health [2]. According to Wang et al. [3], individuals with obesity have a lower life expectancy and have a higher risk of premature death than those with normal weight [4]. Today’s obesity is also a major contributor to public health problems since it increases the risk factors for chronic non-communicable diseases, such as cardiovascular disease, non-alcoholic fatty liver disease, diabetes mellitus type II, and several types of cancer [5, 6].

A study conducted byNota et al. [7] reported that obesity has also been associated with structural and functional changes in the brain. Potential mechanisms in these changes include inflammation and vascular and metabolic changes [8]. Recently, obesity has also been associated with a low-grade inflammatory state [9], [10], [11]. This condition triggers systemic inflammation which becomes an important factor for microglial activation and neuroinflammation in neurodegeneration [12]. This is caused by excess macronutrients in adipose tissue stimulating the release of inflammatory mediators, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), and decreasing the production of anti-inflammatory agents, such as adiponectin [13]. The results of a study conducted by Calabrese et al. [13] indicated that the production of pro-inflammatory cytokines significantly reduces the expression of brain derived neurotrophic factor (BDNF). The decrease in BDNF expression has been widely associated with cognitive dysfunction and dementia [14], [15], [16], [17], [18], [19], [20], [21], [22].
BDNF is the most expressed neurotrophin in the brain and plays a key role in learning and memory, especially in cognitive function [23]. A current study has revealed that activation of tropomyosin receptor kinase B (TrkB) by BDNF can stimulate the signaling pathways of mitogen-activated protein kinase/ERK, phosphatidylinositol 3-kinase/Akt, and phospholipase C-gamma [24]. Intensive investigations into this signaling had been performed since BDNF/TrkB-mediated intracellular signaling is involved in many neuronal aspects [25]. The BDNF regulates brain function and acts as a neuroprotective through the mechanism of increasing neurogenesis, neuronal survival, axonal growth, dendritic growth, synaptic plasticity, neuronal development, and maintenance in the central nervous system neurons [24]. The BDNF is also associated with the pathophysiology of obesity and metabolic syndrome [26]. However, the relationship of BDNF and obesity is still not clearly revealed. The results of the meta-analysis conducted by Sandrini et al. [27] showed that obesity is not associated with a decrease in circulating BDNF levels. However, the study conducted by Goltz et al. [28] reported that BDNF levels are correlated with central obesity. In addition, the relationship between BDNF levels and inflammation levels is still controversial. A study conducted by Patas et al. [29] reported that BDNF levels is correlated with IL-6 levels and has no correlation with TNF-α levels. However, the results of a study conducted by Zhang et al. [30] showed that the BDNF levels are not correlated with IL-6 and TNF-α levels. On this basis, the objective of this study is to analyze the relationship between serum BDNF levels and predictor markers of obesity (body mass index (BMI) and waist to hip ratio [WHR]) and inflammation levels (IL-6 and TNF-α) in adolescent girls with obesity. The authors hypothesized that there is a significant correlation between serum BDNF levels and predictor markers of obesity and inflammation levels in adolescent girls with obesity.

Methods

Research design

The authors used a cross-sectional study method by employing 33 female with obesity aged 19–23 years with BMI >27.5 kg/m², normal blood pressure, normal resting heart rate (RHR), hemoglobin (Hb) normal, and fasting blood glucose (FBG) ≤100 mg/dL. All respondents received information orally and in writing about the research. They were required to fill out and sign an informed consent before participating in the study.

Ethical clearance

All research procedures have been approved by the Health Research Ethics Commission, Faculty of Medicine, Universitas Brawijaya Malang number 81/EC/KEPK–S1/04/2020.

Analysis of obesity predictor markers

The height of the respondents was measured using a stadiometer (SECA, Chino, CA, USA), while the body weight was measured using an electronic scale (Tech 05°, China). The BMI was measured by calculating body weight (kg) divided by height in m² [31]. The blood pressure was measured using an OMRON digital blood pressure meter (OMRON Model HEM-7130 L, Omron Co., Osaka, Japan). The waist circumference (WC) was measured by circling the anthropometric tape measure on the halfway between the lower rib and iliac bones parallel to the midaxillary straight line. The hip circumference (HC) was measured by circling the anthropometric tape measure right on the great trochanters, while the waist to WHR measurement was performed by calculating its WC divided by HC.

Analysis of BDNF and inflammatory levels

The blood was taken from the cubital vein amounted to 4 ml after undergoing overnight fasting for 12 h. The respondents were asked to do sleeping position while the blood was taken. The collected blood was centrifuged for 15 min at 3000 rpm. The serum was separated and stored at −30°C for obtaining an analysis of BDNF, IL-6, and TNF-α levels in the next day. The blood sampling was performed at 07.00–08.00 a.m. (Jakarta time). The measurement of serum BDNF levels was performed using the Enzyme-Linked Immunosorbent Assay (ELISA) kit method (Catalog No. E-EL-H0010; Elabscience, Inc., China) with a standard curve range of 31.25–2000 pg/mL and the sensitivity levels of BDNF in the kit 18.75 pg/mL. The IL-6 levels were measured using ELISA kit method (Catalog No. E-EL-H0102; Elabscience, China) with a standard curve range of 7.81–500 pg/mL and the sensitivity levels of IL-6 in the kit was 4.69 pg/mL. The TNF-α levels were measured using the ELISA kit method (Catalog No. E-EL-H0109; Elabscience, Inc., China) with a standard curve range of 7.81–500 pg/mL and sensitivity 4.69 pg/mL. Blood taking for examination of FBG and Hb levels was carried out in the capillaries located at the tip of the middle finger. The FBG examination was performed using Accu-Chek Performance (Roche, Mannheim, Germany) with the levels of mg/dL, while the Hb examination was performed using Easy Touch GCHb (Easy Touch, Hsinchu, Taiwan) with the levels of g/dL.
Raharjo et al. Negative Correlation between BDNF Levels with Obesity Predictor Markers and Inflammation Levels

**Statistical analysis**

The statistical analysis technique was performed using Statistical Package for the Social Science (SPSS) software version 21 (SPSS Inc., Chicago, IL, USA). The normality test was made using Kolmogorov–Smirnov test. Data with normal distribution were tested using Pearson product-moment with significant levels of p < 0.05. All data were then displayed with the mean ± standard error of the mean.

**Results**

The analysis on the characteristics of respondents showed several results, that is, the mean age (20.76 ± 0.19 years), anthropometric parameters of height (1.57 ± 0.01 m), body weight (73.02 ± 1.48 kg), BMI (29.55 ± 0.52 kg/m²), WC (87.61 ± 2.03 cm), HC (107.58 ± 1.27 cm), WHR (0.80 ± 0.01), SBP (113.82 ± 0.68 mmHg), DBP (76.06 ± 0.85 mmHg), RHR (73.18 ± 1.08 bpm), FBG (88.00 ± 1.04 mg/dL), and Hb (14.65 ± 1.08 g/dL). The mean serum BDNF levels showed (341.33 ± 18.97 pg/mL) and the mean inflammation levels showed IL-6 (10.03 ± 0.79 pg/mL) and TNF-α (17.91 ± 0.40 pg/mL). The relationship between serum BDNF levels and BMI, WHR, IL-6, TNF-α is presented in Figure 1.

Based on Figure 1, the results of the Pearson product-moment linear correlation parametric analysis indicates that there is a negative correlation between serum BDNF levels and BMI (r = –0.759; p < 0.001), WHR (r = –0.675; p < 0.001), IL-6 levels (r = –0.530; p < 0.001), and TNF-α levels (r = –0.561; p < 0.001).

**Discussion**

The results of the analysis showed that there was a negative correlation between serum BDNF levels and BMI and WHR (Figure 1). These results are in line with the results of a study conducted by Si et al. [32] that there is a negative correlation between BMI and BDNF levels in male and female students. A study conducted by Yang et al. [33] also reported that BDNF levels have a significant correlation with BMI in female. Furthermore, a study conducted by Jung et al. [34] confirmed that BDNF levels have a correlation with BMI. Zhang et al. [35], through his study, also reported that BDNF levels are associated with BMI. Goltz et al. [28] in his research also reported that BDNF levels correlated with WHR in obese individuals. These findings confirm that there is a relationship between BDNF levels and predictor markers of obesity. This relationship may be underlined by a significant reduction in BDNF levels in individuals with obesity [36]. The study conducted by El-Alameey et al. [26] proved that children with obesity have a significant decrease in serum BDNF levels. Besides, the study conducted by El-Gharbawy et al. [37] also reported that serum BDNF is lower in children and adolescents with obesity than children and adolescents with normal or ideal weight. The decrease in BDNF levels can inhibit the activation of tropomyosin kinase B (TrkB) receptors and primary BDNF receptors, resulting in hyperphagia and obesity [38]. The inhibition in activation between BDNF and TrkB triggers a series of reactions that inhibit an eager to eat and weight gain [38]. This shows that BDNF has a central role in inhibiting appetite, thereby increasing negative energy balance, and in executing control which is characterized by accelerated cognitive decline and brain atrophy in later years [32].

Based on the results of statistical analysis, there is a negative correlation between serum BDNF levels and inflammation levels (IL-6 and TNF-α) in female with obesity (Figure 1). These results are in line with the results of study conducted by Patas et al. [29] that BDNF levels have a correlation with IL-6 levels, but the BDNF levels do not have a relationship with TNF-α levels in patients with major depressive disorder (MDD). These results are also different from that of the study conducted by Zhang et al. [30] that BDNF levels do not have correlation with IL-6 and TNF-α levels in patients with chronic schizophrenia. The difference may be caused by the fact that this study used female with obesity as the respondents, whereas the previous studies used chronic schizophrenia patients and MDD patients. It has recently been reported that obesity is associated with a low-grade inflammatory state [9], [10], [27]. Such a condition triggers systemic inflammation which
is an important factor for microglial activation and neuroinflammation in neurodegeneration [11]. This may happen due to excess macronutrients in adipose tissue that stimulate the release of pro-inflammatory mediators, such as TNF-α and IL-6 and reduce the production of anti-inflammatory agents, such as adiponectin [12]. The results of a study conducted by Calabrese et al. [13] revealed that an increase in production of pro-inflammatory cytokines significantly reduces the BDNF levels.

Based on the results of a review conducted by Sui and Pasco [39], obesity also has a relationship with a decrease in cognitive function, neuronal plasticity, brain volume, and brain structure. Besides, the changes in BDNF levels are affected by genetic factors, but other evidence also showed that BDNF levels are associated with the changes in lifestyle and dietary habit [39]. An excessive calorie intake as compared to calorie expenditure in the body causes an increase in body weight which is characterized by an increase in white adipose tissue and can also lead to a decrease in the BDNF levels [27]. Having proven by the results of a study by Lee et al. [40], the baseline BDNF levels in individuals with obesity are lower than that of in the individuals without obesity. Furthermore, a study conducted by Si et al. [32] reported that was associated with the decrease in BDNF levels in adolescents aged 18–20 years. Obesity can reduce serum neurotrophic factor levels and cause blood-brain barrier (BBB) dysfunction [41]. This leads to peripheral pro-inflammatory cytokines to pass through the BBB, causing central inflammation that occurs in the brain and causes damage to the nervous system [42].

Conclusion

Based on the results of the study, there is a negative correlation between serum BDNF levels and BMI, WHR, and inflammation levels (IL-6 and TNF-α) in female with obesity. The authors suggest that future researchers can reveal the physiological mechanism of correlation between serum BDNF and BMI, WHR, and inflammation levels (IL-6 and TNF-α) in female with obesity more detail. Further studies are needed to confirm the present findings.

References

1. World Health Organization. Obesity and overweight. Geneva: World Health Organization; 2020. Available from: https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight. https://doi.org/10.1787/a47d60cd2-en [Last accessed on 2021 May 10].
2. María P, Evangelia S. Obesity disease. Health Sci J. 2009;3(3):132-8.
3. Wang C, Chan JS, Ren L, Yan JH. Obesity reduces cognitive and motor functions across the lifespan. Neuroplasticity. 2016;2016:2473081. https://doi.org/10.1155/2016/2473081 PMid:26881095
4. Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med. 2003;138(1):24-32. https://doi.org/10.7326/0003-4819-138-1-200301070-00008
5. Goossens GH. The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function. Obes Facts. 2017;10(3):207-15. https://doi.org/10.1155/2009/0471488
6. Kopelman PG. Obesity as a medical problem. Nature. 2000;404(6778):635-43. https://doi.org/10.1038/35007508 PMid:10766250
7. Nata M, Vreeken D, Wiesmann M, Aarts EO, Hazebrook EJ, Kiliaan AJ. Obesity affects brain structure and function- rescue by bariatric surgery? Neurosci Biobehav Rev. 2020;108:646-57. https://doi.org/10.1016/j.neubiorev.2019.11.025 PMid:31794778
8. Nguyen JC, Killcross AS, Jenkins TA. Obesity and cognitive decline: Role of inflammation and vascular changes. Front Neurosci. 2014;8:375. https://doi.org/10.3389/fnins.2014.00375 PMid:25477778
9. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98-107. https://doi.org.org.10.1038/nri2925 PMid:21233852
10. Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm. 2010;2010:289645. https://doi.org/10.1155/2010/289645 PMid:20706689
11. Ugalde-Muñiz P, Fetter-Fruneda I, Navarro L, García E, Chavarría A. Chronic systemic inflammation exacerbates neurotoxicity in a Parkinson’s disease model. Oxid Med Cell Longev. 2020;2020:4807179. https://doi.org/10.1155/2020/4807179 PMid:32015787
12. Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y. Obesity and inflammation: The linking mechanism and the complications. Arch Med Sci. 2017;13(4):851-63. https://doi.org/10.5114/ams.2016.58928 PMid:28721154
13. Calabrese F, Rossetti AC, Racagni G, Gass P, Riva MA, Molteni R. Brain-derived neurotrophic factor: A bridge between inflammation and neuroplasticity. Front Cell Neurosci. 2014;8:430. https://doi.org/10.3389/fncel.2014.00430 PMid:25565964
14. Pérez LM, Pareja-Galeano H, Sanchis-Gomar F, Emanuele E, Lucia A, Gálvez BG. Adipaging: Ageing and obesity share biological hallmarks related to a dysfunctional adipose tissue. J Physiol. 2016;594(12):3187-207. https://doi.org/10.1113/JP271691 PMid:26926488
15. Weinstein G, Beiser AS, Choi SH, Preis SR, Chen TC, Vargas D, et al. Serum brain-derived neurotrophic factor and its consequences for life expectancy: a life-table analysis. Ann Intern Med. 2003;138(1):24-32. https://doi.org/10.1001/jamauro.2013.4781 PMid:24276217
16. Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 2012;64(2):238-58.
17. Cunha C, Brambilla R, Thomas KL. A simple role for BDNF in learning and memory?. Front Mol Neurosci. 2010;3:1. https://doi.org/10.3389/neuro.02.001.2010

18. Komulainen P, Pedersen M, Hänninen T, Brunsgaard H, Lakka TA, Kiviipelto M, et al. BDNF is a novel marker of cognitive function in ageing female: The DR’s EXTRA study. Neurobiol Learn Memory. 2008;90(4):596-603. https://doi.org/10.1016/j.nblm.2008.07.014

19. Binder DK, Scharman HE. Brain-derived neurotrophic factor. Growth Factors (Chur, Switzerland). 2004;22(3):123-31. https://doi.org/10.1080/08977190410001723308

20. Yamada K, Mizuno M, Nabeshima T. Role for brain-derived neurotrophic factor in learning and memory. Life Sci. 2002;70(7):735-44. https://doi.org/10.1016/s0024-3205(01)01461-8

21. Holsinger RM, Schnarr J, Henry P, Castelo VT, Fahnestock M. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer’s disease. Brain research. Mol Brain Res. 2000;76(2):347-54. https://doi.org/10.1016/s0926-6573(00)00023-1

22. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron. 1991;7(5):695-702. https://doi.org/10.1016/0896-6273(91)90273-3

23. Ieraci A, Beggiaato S, Ferraro L, Barbieri SS, Popoli M. Kynurenine pathway is altered in BDNF Val66Met knock-in mice: Effect of physical exercise. Brain Behav Immunity. 2020;89:440-50. https://doi.org/10.1016/j.bbi.2020.07.031

24. Numakawa T, Odaka H, Adachi N. Actions of brain-derived neurotrophic factor in the neurogenesis and neuronal function, and its involvement in the pathophysiology of brain diseases. Int J Mol Sci. 2018;19(11):3650. https://doi.org/10.3390/ijms19113650

25. Konishi K, Cherkerzian S, Aroner S, Jacobs EG, Rentz DM, Remington A, et al. Impact of BDNF and sex on maintaining intact memory function in early midlife. Neurobiol Aging. 2020;88:137-49. https://doi.org/10.1016/j.neurobiolaging.2019.12.014

26. El-Alameey IR, Ahmed HH, Alzoubi KH, Maikano AB. The importance of physical fitness for the relationship of BDNF with obesity measures in young normal-weight adults. Heliyon. 2020;6(3):e03490. https://doi.org/10.1016/j.heliyon.2020.e03490

27. El-Gharbawy AH, Adler-Wailes DC, Mirch MC, Theim KR, Ranzenhofer L, Tanofsky-Kraff M, et al. Serum brain-derived neurotrophic factor concentrations in lean and overweight children and adolescents. J Clin Endocrinol Metab. 2006;91(9):3548-52. https://doi.org/10.1210/jc.2006-06659

28. Xu B, Goulding EH, Zang K, Cepoi D, Cone RD, Jones KR, et al. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci. 2003;6(7):736-42. https://doi.org/10.1038/nn1073

29. Sandrini L, Di Minno A, Amadio P, Ieraci A, Tremoli E, Barbieri SS. Association between obesity and circulating brain-derived neurotrophic factor (BDNF) levels: Systematic review of competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer’s disease. Brain research. Mol Brain Res. 2000;76(2):347-54. https://doi.org/10.1016/s0024-3205(01)01461-8

30. Alomari MA, Khabour OF, Alawneh KA, Alzoubi KH, Maikano AB. The importance of physical fitness for the relationship of BDNF with obesity measures in young normal-weight adults. Heliyon. 2020;6(3):e03490. https://doi.org/10.1016/j.heliyon.2020.e03490

31. El-Gharbawy AH, Adler-Wailes DC, Mirch MC, Theim KR, Ranzenhofer L, Tanofsky-Kraff M, et al. Serum brain-derived neurotrophic factor concentrations in lean and overweight children and adolescents. J Clin Endocrinol Metab. 2006;91(9):3548-52. https://doi.org/10.1210/jc.2006-06659

32. Xu B, Goulding EH, Zang K, Cepoi D, Cone RD, Jones KR, et al. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci. 2003;6(7):736-42. https://doi.org/10.1038/nn1073

33. El-Gharbawy AH, Adler-Wailes DC, Mirch MC, Theim KR, Ranzenhofer L, Tanofsky-Kraff M, et al. Serum brain-derived neurotrophic factor concentrations in lean and overweight children and adolescents. J Clin Endocrinol Metab. 2006;91(9):3548-52. https://doi.org/10.1210/jc.2006-06659

34. El-Gharbawy AH, Adler-Wailes DC, Mirch MC, Theim KR, Ranzenhofer L, Tanofsky-Kraff M, et al. Serum brain-derived neurotrophic factor concentrations in lean and overweight children and adolescents. J Clin Endocrinol Metab. 2006;91(9):3548-52. https://doi.org/10.1210/jc.2006-06659

35. El-Gharbawy AH, Adler-Wailes DC, Mirch MC, Theim KR, Ranzenhofer L, Tanofsky-Kraff M, et al. Serum brain-derived neurotrophic factor concentrations in lean and overweight children and adolescents. J Clin Endocrinol Metab. 2006;91(9):3548-52. https://doi.org/10.1210/jc.2006-06659
oxidant-antioxidant balance, neurotrophic factor levels, and blood-brain barrier function in obese and non-obese men. J Sport Health Sci. 2017;6(4):447-53. https://doi.org/10.1016/j.jshs.2016.07.006 PMid:30356625

42. Pugazhenthi S, Qin L, Reddy PH. Common neurodegenerative pathways in obesity, diabetes, and Alzheimer’s disease. Biochim Biophys Acta. Molecular basis of disease, 2017;1863(5):1037-45. https://doi.org/10.1016/j.bbadis.2016.04.017 PMid:27156888

Author Query???

AQ1 Kindly provide last accessed date